evaluate the pharmaceuticals company wegovy on glp-1 and insurance providers drug coverage for obesity making inroads with large employers: Mercer Ole Miss researchers study barriers

Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial

Diabetes care portfolio including GLP-1 receptor agonist therapies

Patients and healthcare providers can report suspected adverse events related to these medications to the FDA through the MedWatch program (www.fda.gov/medwatch or 1-800-FDA-1088)

Tirzepatide and semaglutide can have the unfortunate side effect of potential muscle loss alongside their therapeutic effectsparticularly if youre on a long-term weight loss plan

Its a precautionary framing, primarily grounded in cancer risk (IARC Group 1 classification)